Please join us in the New Year for an amazing talk by Andrew Kernytsky entitled "Predicting and Detecting CRISPR Edits: On Target and Off."
Andrew Kernytsky heads up the Computational Biology and Genomics work at CRISPR Therapeutics by staring at edited DNA sequencing data and occasionally making some sense of it. Previously, he brought order to a swarm of cancer genomics data at Agios Pharmaceuticals and saw how it factored into metabolic pathways and drug targets.
Previously, Andrew dove into next-generation sequencing at the Broad Institute of MIT and Harvard. There, he contributed to the creation of a leading system for detecting DNA variants (SNPs and short indels) as well as GATK, a generalized toolkit for analyzing massive genomic data. Some key applications of this toolkit that Andrew has led or contributed to include: detecting de novo mutations in sequenced mother-father-child trios, detecting systematic errors in sequencing data, creating tools that decrease the negative downstream effects of these errors, and optimizing the protocols by which sequencing is targeted to specific areas of the genome.
Before joining the Broad, Andrew completed his Ph.D. at Columbia University in the Burkhard Rost Lab. There, he used genetic algorithms to select combinations of features from a complex space in order to predict protein function. Andrew’s undergraduate work included majors in Chemistry and Biochemistry at La Salle University. During that time, he had the opportunity to work extensively with custom microarray gene expression platforms and Affymetrix arrays at Rhone-Poulenc Rorer and Merck Research Labs. In this work, Andrew split his time between doing laboratory research and computational data exploration and tool development.
This event will be held on Thursday, January 16th, 2020 at 6:00pm at RelayTX.
Please note, this event is capped at 60 people. In order to attend, we need full names for the check list. No one will be admitted after 6:15. Please update your Meetup with your full name or email bagimcommunications@gmail.com.
Additionally, I would like to sincerely apologize for the confusion. The previous announcement was made in error, and was a result of a misread email.
The entire BAGIM team thanks you all for your continued support and for your understanding.
Happy Holidays
Andrew Kernytsky heads up the Computational Biology and Genomics work at CRISPR Therapeutics by staring at edited DNA sequencing data and occasionally making some sense of it. Previously, he brought order to a swarm of cancer genomics data at Agios Pharmaceuticals and saw how it factored into metabolic pathways and drug targets.
Previously, Andrew dove into next-generation sequencing at the Broad Institute of MIT and Harvard. There, he contributed to the creation of a leading system for detecting DNA variants (SNPs and short indels) as well as GATK, a generalized toolkit for analyzing massive genomic data. Some key applications of this toolkit that Andrew has led or contributed to include: detecting de novo mutations in sequenced mother-father-child trios, detecting systematic errors in sequencing data, creating tools that decrease the negative downstream effects of these errors, and optimizing the protocols by which sequencing is targeted to specific areas of the genome.
Before joining the Broad, Andrew completed his Ph.D. at Columbia University in the Burkhard Rost Lab. There, he used genetic algorithms to select combinations of features from a complex space in order to predict protein function. Andrew’s undergraduate work included majors in Chemistry and Biochemistry at La Salle University. During that time, he had the opportunity to work extensively with custom microarray gene expression platforms and Affymetrix arrays at Rhone-Poulenc Rorer and Merck Research Labs. In this work, Andrew split his time between doing laboratory research and computational data exploration and tool development.
This event will be held on Thursday, January 16th, 2020 at 6:00pm at RelayTX.
Please note, this event is capped at 60 people. In order to attend, we need full names for the check list. No one will be admitted after 6:15. Please update your Meetup with your full name or email bagimcommunications@gmail.com.
Additionally, I would like to sincerely apologize for the confusion. The previous announcement was made in error, and was a result of a misread email.
The entire BAGIM team thanks you all for your continued support and for your understanding.
Happy Holidays
No comments:
Post a Comment